Interferon alfa

Phase 3Small molecule

Pfizer

Interferon alfa is one of 137 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

MelanomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

COVID-19Active, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Renal Cell CarcinomaPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Interferon alfa

Pfizer

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Chronic Hepatitis

NCT06926647

Clinical

Trials by Indication[1]

Renal Cell Carcinoma3 trials

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

Completed·CCentre Leon Berard·Phase 3·NCT00291369·456 enrolled

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 3·NCT00065468·626 enrolled

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 3·NCT00083889·750 enrolled

Chronic Hepatitis2 trials

A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting·—··NCT06926647·2,000 enrolled

Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004804·57 enrolled

Melanoma2 trials

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00006237·432 enrolled

Protocol of Clinical Trial of EAFO 2012: Adjuvant Therapy of Skin Melanoma With Use of Alpha Interferon and Naderin

Completed·MMIPO Clinic·Phase 2·NCT07671495·278 enrolled

Radiotherapy1 trial

Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00005615·24 enrolled

Vaccine1 trial

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00363649·36 enrolled

1 more indication

COVID-191 trial

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 3·NCT04534725·441 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Interferon alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interferon alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interferon alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Interferon alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Renal Cell Carcinoma3 trials

Chronic Hepatitis2 trials

Melanoma2 trials

Radiotherapy1 trial

Vaccine1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News